相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
Vivek Subbiah et al.
JCO PRECISION ONCOLOGY (2018)
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
H. A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
Alain Patrick Algazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma
Su Yin Lim et al.
CANCER (2017)
Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets
Xiaosheng Wang et al.
MEDICINE (2016)
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies
Hatice Gungor et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Mutations in the RAS and PI3K Pathways are Associated With Metastatic Location in Colorectal Cancers
Yuan-Tzu Lan et al.
JOURNAL OF SURGICAL ONCOLOGY (2015)
Integrated network model provides new insights into castration-resistant prostate cancer
Yanling Hu et al.
SCIENTIFIC REPORTS (2015)
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
Melissa Dumble et al.
PLOS ONE (2014)
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Characterization of a Chemical Affinity Probe Targeting Akt Kinases
Fiona Pachl et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
Irene Sanchez-Hernandez et al.
CANCER LETTERS (2012)
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich et al.
CANCER RESEARCH (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
The functions and regulation of the PTEN tumour suppressor
Min Sup Song et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey et al.
ONCOTARGET (2012)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A parallel phase I/II clinical trial design for combination therapies
Xuelin Huang et al.
BIOMETRICS (2007)
分享论文
